Rachana Pradhan

Visit kff.org to read Rachana's bio.

rpradhan@kff.org
@rachanadpradhan

Hospitales le piden a Santa suministros: falta de todo, desde sillas de ruedas hasta jeringas

KFF Health News Original

En otra consecuencia de la crisis de la cadena de suministro global, hospitales que gestionan los picos de casos de covid durante las Fiestas y a todos sus otros pacientes se están quedando sin suministros básicos para atenderlos

Pharma Campaign Cash Delivered to Key Lawmakers With Surgical Precision

KFF Health News Original

With an eye to shutting down Medicare drug price negotiations, drug companies and their lobbying groups gave roughly $1.6 million in the first six months of 2021, with Democrats edging closer than they have in a decade to Republicans’ total haul.

Community Clinics Shouldered Much of the Vaccine Rollout. Many Haven’t Been Paid.

KFF Health News Original

Federally qualified health centers from California to Michigan are mired in a bureaucratic mess over how they should be paid under Medicaid for each dose of covid vaccine given. In California alone, clinics await reimbursement for at least 1 million shots, causing a “massive cash flow problem.”

To Quarantine or Not: The Hard Choices Schools Are Leaving to Parents and Staff

KFF Health News Original

Back-to-school season has fueled immediate covid outbreaks. Instead of beefing up protections, some districts are letting students go without masks, physical distancing and quarantines. And parents are left to make impossibly tough decisions.

Novavax’s Effort to Vaccinate the World, From Zero to Not Quite Warp Speed

KFF Health News Original

Novavax is a vaccine company that, despite $2 billion in new federal and international funding, still hasn’t come through with a licensed covid vaccine. It hopes it can still help to fight the global covid scourge, but will it deliver?

After Billions of Dollars and Dozens of Wartime Declarations, Why Are Vaccines Still in Short Supply?

KFF Health News Original

The Trump and Biden administrations both imposed wartime production requirements. But industry experts say the vast quantities of raw materials and specialty equipment needed for billions of newfangled vaccines have required herculean logistical efforts.